Mark Boldin
Weizmann Institute of Science
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Boldin.
Cell | 1996
Mark Boldin; Tanya Goncharov; Yury V Goltseve; David Wallach
Fas/APO-1 and p55 tumor necrosis factor (TNF) receptor (p55-R) activate cellular mechanisms that result in cell death. Upon activation of these receptors, Fas/APO-1 binds a protein called MORT1 (or FADD) and p55-R binds a protein called TRADD. MORT1 and TRADD can also bind to each other. We have cloned a novel protein, MACH, that binds to MORT1. This protein exists in multiple isoforms, some of which contain a region that has proteolytic activity and shows marked sequence homology to proteases of the ICE/CED-3 family. Cellular expression of the proteolytic MACH isoforms results in cell death. Expression of MACH isoforms that contain an incomplete ICE/CED-3 region provides effective protection against the cytotoxicity induced by Fas/APO-1 or p55-R triggering. These findings suggest that MACH is the most upstream enzymatic component in the Fas/APO-1- and p55-R-induced cell death signaling cascades.
FEBS Letters | 1995
Mark Boldin; Igor Mett; David Wallach
A novel protein that binds specifically to the intracellular domain of the p55 tumor necrosis factor (TNF) receptor was cloned by two‐hybrid screening of a HeLa cell cDNA library. Data bank searches revealed high sequence similarity of the protein (55.11) to yeast, nematode and plant proteins, whose functions are yet unknown. Significant similarity was also found between 55.11 and SEN3, the yeast equivalent of the p112 subunit of the 26S proteasome. Deletion analysis showed that the protein binds to the p55 receptor upstream to the region involved in induction of cell death.
Current Opinion in Immunology | 1998
David Wallach; Mark Boldin; Andrei Kovalenko; Nikolai Malinin; Igor Mett; Jacques Camonis
The yeast two-hybrid technique provides a general approach for cloning cDNAs merely by exploiting the ability of their encoded proteins to bind to a protein of interest. The technique therefore offered a useful access to the analysis of the mechanisms of cell death at the initial stage of their study, when only a few of the proteins involved and very little about their mode of action were known. Conversely, the knowledge of cell death mechanisms gained by this technique provided a useful insight into both the potential and the limitations of this technique.
Annual Review of Immunology | 1999
David Wallach; Eugene Varfolomeev; Nikolai Malinin; Yuri V. Goltsev; and A. V. Kovalenko; Mark Boldin
Nature | 1997
Nikolai Malinin; Mark Boldin; Andrei Kovalenko; David Wallach
Journal of Biological Chemistry | 1995
Mark Boldin; Eugene Varfolomeev; Zeev Pancer; Igor Mett; Jacques Camonis; David Wallach
Journal of Biological Chemistry | 1995
Mark Boldin; Igor Mett; Eugene Varfolomeev; Irina Chumakov; Y Shemer-Avni; Jacques Camonis; David Wallach
Trends in Biochemical Sciences | 1995
Elena Feinstein; Adi Kimchi; David Wallach; Mark Boldin; Eugene Varfolomeev
FEBS Letters | 1997
David Wallach; Mark Boldin; Eugene Varfolomeev; Rudi Beyaert; Peter Vandenabeele; Walter Fiers
Journal of Experimental Medicine | 1996
Eugene Varfolomeev; Mark Boldin; Tanya Goncharov; David Wallach